https://www.fiercebiotech.com/partnering/bristol-myers-lends-opdivo-to-a-combo-neon-s-neoantigen-attack-on-cancer
Bristol-Myers lends Opdivo to a combo with Neon's neoantigen attack on cancer | Fierce Biotech
Dec 15, 2015 - A little more than two months after launching with a $55 million bankroll and a plan to develop next-gen cancer vaccines and immunotherapies, Third Rock...
https://www.precedenceresearch.com/table-of-content/6984
Neoantigen Cancer Vaccine Market Size to Hit USD 1,799.21 Million by 2034
The global neoantigen cancer vaccine market size is evaluated at USD 475.68 million in 2025 and is predicted to hit around USD 1,799.21 million by 2034,...
https://www.prnewswire.com/news-releases/genscript-expands-peptide-production-capabilities-to-include-neoantigen-peptides-and-apis-301895270.html
GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs
/PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has ramped up production of complex...
production capabilitiesgenscriptexpandspeptide
https://elifesciences.org/articles/85263
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against...
In vivo modeling of neoantigen-restricted heterogeneity shows that clonal expression of neoantigens enhances anti-tumor T cell responses by increasing the...
cross presentationdendritic cells
https://straitsresearch.com/report/neoantigen-cancer-vaccine-market/request-sample
Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2033
cancer vaccinemarket analysisneoantigensizereport
https://pmc.ncbi.nlm.nih.gov/articles/PMC10859690/
ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen...
Neoantigens are derived from somatic mutations in the tumors but are absent in normal tissues. Emerging evidence suggests that neoantigens can stimulate...
a machine
https://pmc.ncbi.nlm.nih.gov/articles/PMC8273876/
Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in...
Personal neoantigen vaccines have been envisioned as an effective approach to induce, amplify, and diversify antitumor T cell responses. To define the...
memory t cell
https://www.jci.org/assets/347421/powerpoint
JCI - Neoantigen identification strategies enable personalized immunotherapy in refractory solid...
personalized immunotherapyjcineoantigenidentificationstrategies
https://international-neoantigen-summit.com/
9th International Neoantigen Summit | 21-23 July, 2026
Join the 9th International Neoantigen Summit 2026 to explore breakthroughs in neoantigen discovery, personalised cancer vaccines, and immunotherapy. Connect...
21 239thinternationalneoantigensummit
https://www.fredhutch.org/en/news/spotlight/2024/01/ccsg-biernacki-jimmunothercancer.html
From predicted neoantigen to T cell therapy for acute myeloid leukemia - Fred Hutch
Jan 22, 2024 - Splicing factor mutants provide an untapped reservoir of neoantigens compatible with T cell-based therapy for secondary acute myeloid leukemia.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12764431/
A microenvironment-driven HLA-II-associated insulin neoantigen elicits persistent memory T cell...
The antigenic landscape of autoimmune diabetes reflects a failure to preserve self-tolerance, yet how novel neoantigens emerge in humans remains incompletely...
https://www.bruker.com/es/news-and-events/webinars/2024/neoantigen-identification-a-microfluidics-assisted-workflow-for-fine-needle-biopsies.html
Neoantigen Identification: A Microfluidics-Assisted Workflow for Fine Needle Biopsies | Bruker
During this GEN webinar, Dr. Joseph Ndika presents a methodology utilizing Valo Therapeutics' groundbreaking microfluidics-based immunoaffinity platform...
neoantigenidentificationmicrofluidicsassisted
https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in/
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy,...
Apr 17, 2026 - mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with...
mrna 4157 v940
https://www.dana-farber.org/clinical-trials/17-105
A Pilot Study of a Personalized Neoantigen Cancer Vaccine with and without Low-Dose...
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions...
https://www.cancer.gov/news-events/cancer-currents-blog/2025/neoantigen-vaccine-pancreatic-kidney-cancer
Neoantigen Vaccines Keep Kidney, Pancreatic Cancer at Bay - NCI
In small trials, neoantigen-based treatment vaccines appeared to prevent cancer from returning in patients who had successful surgery to remove their tumors.
pancreatic cancerneoantigenvaccineskeepkidney
https://pmc.ncbi.nlm.nih.gov/articles/PMC8583296/
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic...
Tumor involvement of major vascular structures limits surgical options in pancreatic adenocarcinoma (PDAC), which in turn limits opportunities for cure....
implantationneoantigentargetedhydrogelvaccine